Drugs / Calcium Dobesilate
Calcium Dobesilate
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00945373 | Jul 2009 → May 2010 | rosacea | Ellen Marmur | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05305508 | May 2022 → Nov 2023 | COVID-19 | Hervé SPECHBACH | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06707051 | Jan 2022 → Dec 2023 | agranulocytosis, digestive system disorder, endometrial disorder, hemorrhagic disease +1 | District Headquarters Teaching Hospital Sahiwal | Completed | No outcome recorded |
| Phase 2/3 | NCT03167918 | Jul 2014 → Apr 2017 | type 2 diabetes mellitus | Liaoning University of Traditional Chinese Medicine | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT03139422 | Jul 2017 → Oct 2018 | menstrual disorder | Assiut University | Unknown | No outcome recorded |
| Phase 3 | NCT00979836 | Apr 2008 → Jul 2010 | ulcer disease | Fundacion Iberoamericana Itaca | Suspended | No outcome recorded Stop: Business |
| Phase 43 trials | ||||||
| Phase 4 | NCT07390097 | Feb → Aug 2026 overdue | chronic venous insufficiency, varicose disease | Oguz Arslanturk | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04283162 | Mar 2020 → Dec 2021 | diabetic retinopathy | Zhongda Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01382498 | Nov 2009 → Jun 2011 | diabetic retinopathy | Tabriz University | Unknown | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2/3 | NCT02290002 Comparator | Jun 2014 → Dec 2016 | infertility disorder | khalid abd aziz mohamed | Completed | No outcome recorded |
| Phase 2/3 | NCT02271360 Comparator | Apr 2014 → Dec 2015 | infertility disorder | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT05095922 Background | Mar 2023 → May 2024 | diabetic peripheral angiopathy, type 2 diabetes mellitus | Affiliated Hospital of Nantong University | Completed | No outcome recorded |
| Phase 4 | NCT03427944 Comparator | Jan 2015 → Dec 2018 | chronic renal failure syndrome | The Affiliated Hospital of Xuzhou Medical University | Unknown | No outcome recorded |
| Phase 4 | NCT03962296 Comparator | Nov 2012 → Jan 2015 | diabetic retinopathy | Hanyang University | Completed | No outcome recorded |
| — | NCT06763094 Comparator | Jan → Nov 2025 overdue | menstrual disorder, uterine anomalies | University of Health Sciences Lahore | Not yet recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Calcium Dobesilate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05095922 ↗ |
| Known as | 2,5-dihydroxybenzene sulfonate | “calcium dobesilate (2,5-dihydroxybenzene sulfonate) is a drug that inhibits vascular smooth muscle cell growth and inhibits cellular proliferation.” NCT00945373 ↗ |
| Known as | CaD | “Calcium dobesilate (CaD) is a well-established, widely available vasoactive and angioprotective drug interacting with heparan sulphate, with the potential to interfere with the...” PMID 38719313 ↗ May 20241“Calcium dobesilate (CaD) has been used in the treatment of diabetic retinopathy (DR) due to its potential in protecting against retinal vascular damage.” PMID 34049911 ↗ May 2021 |
| Known as | Doxium | “Three daily oral doses of 50mg tablets of Calcium Dobesilate(Doxium®, Ilsung Pharm, Seoul, South Korea) were administered to patients in this group” NCT03962296 ↗3“Calcium dobesilate (Doxium)” NCT06763094 ↗ “Calcium dobesilate (Doxium)” NCT01382498 ↗ “Calcium dobesilate (Doxium)” NCT06707051 ↗ |
| Action | Inhibit | “As a synthetic inhibitor of fibroblast growth factor (FGF)” NCT00945373 ↗ |
| Route | Oral | “500 mg/ three times/day for 6 months (capsules)” NCT00979836 ↗ |